CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients
Journal of Virology · 17.09.2024 · 98 (9)
DOI: 10.1128/jvi.00128-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 17.09.2024. Verfasst von Caio César Barbosa Bomfim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mucosal Entry of HIV-1 and Mucosal Immunity, Department of Infection, Immunity and Inflammation, Cochin Institute, Paris, France. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, SARS-CoV-2, COVID-19, Epithelial Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sidaction.
Abstract (Originalsprache)
Upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients with critical coronavirus disease 2019 (COVID-19) present with life-threatening respiratory distress, pulmonary damage, and cytokine storm. One unexplored component in COVID-19 is the neuropeptide calcitonin gene-related peptide (CGRP), which is highly abundant in the airways and could converge in multiple aspects of COVID-19-related pulmonary pathophysiology. Whether CGRP affects SARS-CoV-2 infection directly remains elusive. We show that in critical COVID-19 patients, CGRP is increased in both plasma and lungs. Importantly, CGRP pulmonary levels are elevated in early SARS-CoV-2-positive patients and restored to baseline upon subsequent viral clearance in SARS-CoV-2-negative patients. We further show that CGRP and its stable analog SAX directly inhibit infection of bronchial Calu-3 epithelial cells with SARS-CoV-2 Omicron and Alpha variants in a dose-dependent manner. Both pre- and post-infection treatments with CGRP and/or SAX are enough to block SARS-CoV-2 productive infection of Calu-3 cells. CGRP-mediated inhibition occurs via activation of the CGRP receptor and involves down-regulation of both SARS-CoV-2 entry receptors at the surface of Calu-3 cells. Together, we propose that increased pulmonary CGRP mediates beneficial viral clearance in critical COVID-19 patients by directly inhibiting SARS-CoV-2 propagation. Hence, CGRP-based interventions could be harnessed for management of COVID-19. IMPORTANCE The neuropeptide CGRP is highly abundant in the airways. Due to its immunomodulatory, vasodilatory, and anti-viral functions, CGRP could affect multiple aspects of COVID-19-related pulmonary pathophysiology. Yet, the interplay between CGRP and SARS-CoV-2 during COVID-19 remains elusive. Herein, we show that pulmonary levels of CGRP are increased in critical COVID-19 patients, at an early stage of their disease when patients are SARS-CoV-2-positive. Upon subsequent viral clearance, CGRP levels are restored to baseline in SARS-CoV-2-negative patients. We further show that pre- and post-infection treatments with CGRP directly inhibit infection of Calu-3 bronchial epithelial cells with SARS -CoV-2, via activation of the CGRP receptor leading to decreased expression of both SARS-CoV-2 entry receptors. Together, we propose that increased pulmonary CGRP is beneficial in COVID-19, as CGRP-mediated inhibition of SARS-CoV-2 infection could contribute to viral clearance in critical COVID-19 patients. Accordingly, CGRP-based formulations could be useful for COVID-19 management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mucosal Entry of HIV-1 and Mucosal Immunity, Department of Infection, Immunity and Inflammation, Cochin Institute, Paris, France.
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
- Host-Virus Interactions, Department of Infection, Immunity and Inflammation, Cochin Institute, Paris, France.
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Epoqe Pharma, Copenhagen, Denmark.
- Service of Virology, AP-HP Hôpital Cochin, Paris, France.
ORCID-Profile: Morgane Bomsel, Yonatan Ganor
Förderung
- Sidaction
Zitieren
APA
Barbosa Bomfim, C. C., Génin, H., Cottoignies-Callamarte, A., Gallois-Montbrun, S., Murigneux, E., Sams, A., Rosenberg, A. R., Belouzard, S., Dubuisson, J., Kosminder, O., Pène, F., Terrier, B., Bomsel, M., & Ganor, Y. (2024). CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients. Journal of Virology, 98(9). https://doi.org/10.1128/jvi.00128-24
Vancouver
Barbosa Bomfim CC, Génin H, Cottoignies-Callamarte A, Gallois-Montbrun S, Murigneux E, Sams A, et al. CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients. Journal of Virology. 2024;98(9). doi:10.1128/jvi.00128-24
BibTeX
@article{BarbosaBomfim2024,
author = {Barbosa Bomfim, Caio César and Génin, Hugo and Cottoignies-Callamarte, Andréa and Gallois-Montbrun, Sarah and Murigneux, Emilie and Sams, Anette and Rosenberg, Arielle R and Belouzard, Sandrine and Dubuisson, Jean and Kosminder, Olivier and Pène, Frédéric and Terrier, Benjamin and Bomsel, Morgane and Ganor, Yonatan},
title = {CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients},
journal = {Journal of Virology},
year = {2024},
volume = {98},
number = {9},
doi = {10.1128/jvi.00128-24}
}
EUVIMED